Pulse Biosciences, Inc.
PLSE
$26.06
$1.696.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 751.00K | 350.00K | 86.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 751.00K | 350.00K | 86.00K | -- | -- |
| Cost of Revenue | 909.00K | 539.00K | 279.00K | -- | -- |
| Gross Profit | -158.00K | -189.00K | -193.00K | -- | -- |
| SG&A Expenses | 30.89M | 32.03M | 34.30M | 31.47M | 27.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.80M | 77.29M | 79.03M | 72.24M | 63.69M |
| Operating Income | -78.05M | -76.94M | -78.95M | -72.24M | -63.69M |
| Income Before Tax | -74.57M | -72.78M | -74.73M | -68.03M | -60.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.57 | -72.78 | -74.73 | -68.03 | -60.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.57M | -72.78M | -74.73M | -68.03M | -60.24M |
| EBIT | -78.05M | -76.94M | -78.95M | -72.24M | -63.69M |
| EBITDA | -77.00M | -75.87M | -77.85M | -71.10M | -62.52M |
| EPS Basic | -1.10 | -1.08 | -1.14 | -1.06 | -0.97 |
| Normalized Basic EPS | -0.69 | -0.68 | -0.71 | -0.66 | -0.61 |
| EPS Diluted | -1.10 | -1.08 | -1.14 | -1.06 | -0.97 |
| Normalized Diluted EPS | -0.69 | -0.68 | -0.71 | -0.66 | -0.61 |
| Average Basic Shares Outstanding | 270.44M | 269.58M | 263.84M | 257.52M | 247.43M |
| Average Diluted Shares Outstanding | 270.44M | 269.58M | 263.84M | 257.52M | 247.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |